JP7794807B2 - 気道疾患の治療に使用するための(1r,3s)-3-((5-シアノ-4-フェニルチアゾール-2-イル)カルバモイル)シクロペンタン-1-カルボン酸およびその誘導体 - Google Patents

気道疾患の治療に使用するための(1r,3s)-3-((5-シアノ-4-フェニルチアゾール-2-イル)カルバモイル)シクロペンタン-1-カルボン酸およびその誘導体

Info

Publication number
JP7794807B2
JP7794807B2 JP2023512647A JP2023512647A JP7794807B2 JP 7794807 B2 JP7794807 B2 JP 7794807B2 JP 2023512647 A JP2023512647 A JP 2023512647A JP 2023512647 A JP2023512647 A JP 2023512647A JP 7794807 B2 JP7794807 B2 JP 7794807B2
Authority
JP
Japan
Prior art keywords
asthma
compound
treatment
pharmaceutical composition
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023512647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538419A (ja
JP2023538419A5 (cg-RX-API-DMAC7.html
Inventor
フリオ、カストロ、パロミノ、ラリア
フアン、カマーチョ、ゴメス
ナオミ、カストロ、パロミノ、ラリア
アリーナ、アリオサ、アルバレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palobiofarma SL
Original Assignee
Palobiofarma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma SL filed Critical Palobiofarma SL
Publication of JP2023538419A publication Critical patent/JP2023538419A/ja
Publication of JP2023538419A5 publication Critical patent/JP2023538419A5/ja
Application granted granted Critical
Publication of JP7794807B2 publication Critical patent/JP7794807B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2023512647A 2020-08-21 2021-08-20 気道疾患の治療に使用するための(1r,3s)-3-((5-シアノ-4-フェニルチアゾール-2-イル)カルバモイル)シクロペンタン-1-カルボン酸およびその誘導体 Active JP7794807B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382764.7A EP3957308A1 (en) 2020-08-21 2020-08-21 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
EP20382764.7 2020-08-21
PCT/EP2021/073133 WO2022038261A1 (en) 2020-08-21 2021-08-20 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Publications (3)

Publication Number Publication Date
JP2023538419A JP2023538419A (ja) 2023-09-07
JP2023538419A5 JP2023538419A5 (cg-RX-API-DMAC7.html) 2024-07-29
JP7794807B2 true JP7794807B2 (ja) 2026-01-06

Family

ID=72234795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512647A Active JP7794807B2 (ja) 2020-08-21 2021-08-20 気道疾患の治療に使用するための(1r,3s)-3-((5-シアノ-4-フェニルチアゾール-2-イル)カルバモイル)シクロペンタン-1-カルボン酸およびその誘導体

Country Status (20)

Country Link
US (1) US20230321053A1 (cg-RX-API-DMAC7.html)
EP (2) EP3957308A1 (cg-RX-API-DMAC7.html)
JP (1) JP7794807B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230054444A (cg-RX-API-DMAC7.html)
CN (1) CN115942933A (cg-RX-API-DMAC7.html)
AU (1) AU2021327728B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023002778A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190081A1 (cg-RX-API-DMAC7.html)
DK (1) DK4199922T3 (cg-RX-API-DMAC7.html)
ES (1) ES3001104T3 (cg-RX-API-DMAC7.html)
FI (1) FI4199922T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241621T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069338T2 (cg-RX-API-DMAC7.html)
LT (1) LT4199922T (cg-RX-API-DMAC7.html)
MX (1) MX2023002156A (cg-RX-API-DMAC7.html)
PL (1) PL4199922T3 (cg-RX-API-DMAC7.html)
PT (1) PT4199922T (cg-RX-API-DMAC7.html)
RS (1) RS66263B1 (cg-RX-API-DMAC7.html)
SI (1) SI4199922T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022038261A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009529539A (ja) 2006-03-07 2009-08-20 エンダセア, インコーポレイテッド 呼吸器障害を治療するための方法および組成物
JP2010540615A (ja) 2007-10-02 2010-12-24 パロビオファルマ,エス.エル. アデノシンa1レセプターアンタゴニストとしての新規化合物
WO2016040007A1 (en) 2014-09-08 2016-03-17 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
JP2019203009A (ja) 2013-10-15 2019-11-28 アストラゼネカ アクチボラグ ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
JP2020505349A (ja) 2017-01-20 2020-02-20 パロビオファルマ、ソシエダッド、リミターダPalobiofarma S.L アデノシンa3受容体の調節剤
JP2020509066A (ja) 2017-03-06 2020-03-26 パロビオファルマ、ソシエダッド、リミターダPalobiofarma S.L (1r,3s)−3−(5−シアノ−4−フェニル−1,3−チアゾール−2−イルカルバモイル)シクロペンタンカルボン酸のアミン塩

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009529539A (ja) 2006-03-07 2009-08-20 エンダセア, インコーポレイテッド 呼吸器障害を治療するための方法および組成物
JP2010540615A (ja) 2007-10-02 2010-12-24 パロビオファルマ,エス.エル. アデノシンa1レセプターアンタゴニストとしての新規化合物
JP2019203009A (ja) 2013-10-15 2019-11-28 アストラゼネカ アクチボラグ ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
WO2016040007A1 (en) 2014-09-08 2016-03-17 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
JP2020505349A (ja) 2017-01-20 2020-02-20 パロビオファルマ、ソシエダッド、リミターダPalobiofarma S.L アデノシンa3受容体の調節剤
JP2020509066A (ja) 2017-03-06 2020-03-26 パロビオファルマ、ソシエダッド、リミターダPalobiofarma S.L (1r,3s)−3−(5−シアノ−4−フェニル−1,3−チアゾール−2−イルカルバモイル)シクロペンタンカルボン酸のアミン塩

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Current Pharmaceutical Design,2019年,Vol. 25, No. 26,pp.2792-2807
European journal of pharmacology,2006年,Vol. 551, No. 1-3,pp.116-124
Trends in pharmacological sciences,2009年,Vol. 30, No. 10,pp.528-535

Also Published As

Publication number Publication date
JP2023538419A (ja) 2023-09-07
AU2021327728B2 (en) 2026-06-11
PL4199922T3 (pl) 2025-02-10
WO2022038261A1 (en) 2022-02-24
DK4199922T3 (da) 2024-11-25
CA3190081A1 (en) 2022-02-24
KR20230054444A (ko) 2023-04-24
RS66263B1 (sr) 2024-12-31
EP3957308A1 (en) 2022-02-23
BR112023002778A2 (pt) 2023-03-14
HRP20241621T1 (hr) 2025-01-31
CN115942933A (zh) 2023-04-07
SI4199922T1 (sl) 2025-03-31
US20230321053A1 (en) 2023-10-12
PT4199922T (pt) 2024-12-18
AU2021327728A1 (en) 2023-03-09
LT4199922T (lt) 2025-01-10
MX2023002156A (es) 2023-03-01
EP4199922A1 (en) 2023-06-28
EP4199922B1 (en) 2024-09-25
ES3001104T3 (es) 2025-03-04
FI4199922T3 (fi) 2024-12-05
HUE069338T2 (hu) 2025-02-28

Similar Documents

Publication Publication Date Title
US20220152057A1 (en) Methods and compositions for treating various disorders
RU2766577C2 (ru) Способы лечения эозинофильного эзофагита
JP2505944B2 (ja) (S)―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
EA034864B1 (ru) Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
US20240398809A1 (en) Treatment of alopecia areata
CN116419746A (zh) 右旋普拉克索用于治疗中度至重度哮喘的用途
EP4199922B1 (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
US20200253959A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
US11160814B1 (en) Methods of treatment for disease from coronavirus exposure
TW202539683A (zh) 透過投予(r)-2[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑並[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧雜環丁烷-3-基)哌𠯤-1-基]戊-2-烯腈治療中度至重度氣喘
JP2023538419A5 (cg-RX-API-DMAC7.html)
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
HK40091313A (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
HK40091313B (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
EA048711B1 (ru) (1r,3s)-3-((5-циано-4-фенилтиазол-2-ил)карбамоил)циклопентан-1-карбоновая кислота и ее производные для применения в лечении заболеваний дыхательных путей
US20220054509A1 (en) Methods of treatment for disease from coronavirus exposure
AU2022469413A1 (en) Methods of administering belumosudil for treatment of chronic graft versus host disease
WO2026052051A1 (zh) 杂环化合物在治疗肺疾病中的应用
HK40090654A (en) Use of dexpramipexole for the treatment of moderate to severe asthma
EA051453B1 (ru) Способы лечения и профилактики рассеянного склероза с применением соединений замещенного аминопиримидина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251218

R150 Certificate of patent or registration of utility model

Ref document number: 7794807

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150